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Background: Partially paralyzed patients may be placed in the risk of pharyngeal dysfunction. Bupivacaine acts 
as acetylcholine receptor ion channel blocker and may synergistically interact with rocuronium to augment NM 
blockade. Thus, this study aims to elucidate whether or not, at a therapeutic concentration, bupivacaine by itself may 
cause NM blockade and reduce an effective concentration of rocuronium.
Methods: Twenty-two left phrenic nerve-hemidiaphragms (Male SD rats, 150-250 g) were hung in Krebs solution. 
Three consecutive ST, 0.1 Hz and one TT, 50 Hz for 1.9 s were obtained before drug application and at each new drug 
concentration. A concentration of bupivacaine in Krebs solution (n = 5) was cumulatively increased by way of 0.01, 
0.1, 1, (1, 2, 3, 4, 5, 6, 7) × 10 μM. In a Krebs solution, pre-treated with bupivacaine 0 (n = 5), 0.1 (n = 5), 1.0 (n = 5), 10 (n 
= 2) μM, and then concentrations of rocuronium were cumulatively increased by way of 1, 3, 5, 7, 9, 12, 14, 16, 18, 20 
μM. EC for each experiment were determined by a probit. The EC50’s of rocuronium were compared using a Student’s 
t-test with Bonferroni’s correction. Differences were considered significant when P < 0.05.
Results: The potency of bupivacaine for normalized TF was 11.4 (± 1.1) μM. Below 30 μM of bupivacaine, the single 
twitch potentiation sustained despite the development of tetanic fade and partial inhibition of PTT. Bupivacaine 
significantly facilitated the NM blockade induced by rocuronium.
Conclusions: Clinicians should be aware that bupivacaine by itself at its therapeutic concentration inhibit NM 
conduction and enhances rocuronium-induced muscle relaxation. (Korean J Anesthesiol 2012; 62: 468-473)
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Introduction
Sundman et al. [1] showed that after recovery to a train-
of-four ratio of more than 0.90, the incidence of pharyngeal 
dysfunction was 13%, and the majority (80%) of pharyngeal 
dysfunction resulted in laryngeal penetration. Thus, 
bupivacaine may inhibit neuromuscular conduction, and com-
bining it with other drugs, which interrupt the neuro  muscular 
(NM) conduction, would place the patients at risk of muscle 
relaxation.
Local anesthetics (LAs) primarily inhibit voltage-gated Na
+ 
channels [2]. However, LAs noncompetitively inhibit the ion 
channel activity of muscle-type nicotinic acetylcholine receptor 
(AChR) at therapeutic dose [3,4] and ACh synthesis in nerve 
terminal [5]. There seems to be a few studies conducted on NM 
blockade created by bupivacaine.
Some investigators indicated that lidocaine failed to show a 
sparing effect on cisatracurium requirements [6,7]. However, 
it has been known that some local anesthetics potentiate 
nondepolarizing NM blockers [8-11]. Bupivacaine and rocuro-
nium are regarded as NM blocker: bupivacaine acts as an AChR-
ion channel blocker, and rocuronium as AChR blocker. Because 
of their different acting sites, the two drugs may synergistically 
interact to produce more NM blockade than expected. Based 
on this premise, it could be hypothesized that bupivacaine 
enhances rocuronium-induced NM blockade.
Thus, this study aims to elucidate whether or not, at a clinical 
therapeutic concentration, bupivacaine by itself may induce 
NM blockade and reduce an effective concentration of rocuro-
nium.
Materials and Methods
The Institutional Animal Care and Use Committee approved 
the experimental protocol. All experimental courses followed 
the Guide for the Care and Use of Laboratory Animals 
provided by the National Academy of Sciences. Twenty-two 
male Sprague-Dawley rats (5-7 weeks in age, and 150-250 
g in weight) were anesthetized by a perivertebral injection of 
propofol (50 mg/kg) at the lumbar level and then sacrificed. 
The phrenic nerve and diaphragm were excised together and 
the left diaphragm with the middle diaphragmatic ligament was 
separated from the rest of the diaphragm. Left phrenic nerve-
hemidiaphragm preparations were hung in a 20 ml organ bath 
that had been filled with Krebs solution (118 mM NaCl, 5 mM 
KCl, 2.5 mM CaCl2, 30 mM NaHCO3, 1 mM KH2PO4, 1 mM 
MgCl2 and 11 mM glucose).
The bath solution was maintained at 32
oC and was con-
tinuously aerated with a gas mixture of 95% oxygen and 5% 
carbon dioxide. The pH of the bath solution was maintained 
at 7.38 to 7.42. Spent Krebs solution was exchanged with fresh 
solution 10 min after the preparation was mounted. The pre-
paration was attached to a force transducer (Model 1030, UFI, 
Morro Bay, CA, USA) with a stainless steel wire and was allowed 
to stabilize for 20 min in the bath. The phrenic nerve, connected 
to an electrode, was stimulated with supramaximal square 
wave impulses in duration of 0.2 ms, using a stimulator (Model 
ML112, ADInstruments Pty Ltd, Bella Vista, NSW, Australia). 
The diaphragm muscle was stretched until the maximum 
output tension was measured after stimulation, followed by 
another 10 min for stabilization before each experiment began. 
Before drug application for a baseline and at each new drug 
concentrations, there were three consecutive single twitches 
(ST) at 0.1 Hz and a 1.9 s tetanic tension of 50 Hz recorded, 
which were then digitized and stored on a Power Macintosh 
7100 (Apple Computer Corp, Cupertino, CA, USA) using data 
acquisition software (MacLab, ADInstruments Pty Ltd, Bella 
Vista, NSW, Australia).
After baseline tensions were measured, the concentrations 
of bupivacaine in Krebs solution (n = 5) were cumulatively 
increased by the way of 0.01, 0.1, 1, (1, 2, 3, 4, 5, 6, 7) × 10 μM, 
until an 80% to 90% reduction in ST was reached.
In order to determine whether bupivacaine would enhance 
rocuronium-induced NM blockade, Krebs solutions had been 
pre-mixed with 0 (n = 5), 0.1 (n = 5), 1.0 (n = 5), 10 (n = 2) μM 
bupivacaine, and then the concentrations of rocuronium were 
cumulatively increased by the way of 1, 3, 5, 7, 9, 12, 14, 16, 18, 
20 μM until an 80 to 90% reduction in ST was reached.
A period of at least 20 min was allowed to pass to establish 
a pseudo-steady state of every drug concentration between 
bath and muscle. Tension measurements were made during 
the pseudo-steady state and in the drug-free solution after 
completion of each experiment. The data were analyzed only 
if the ST tension returned to greater than 90% of the baseline 
recording in a drug-free solution.
Mean ST tension was gathered by averaging the three 
consecutive measurements, and peak tetanic tension (PTT) 
was measured at 0.2 s after start of tetanic stimulation. The 
effect of the drug on ST tension, PTT, and tetanic fade (TF) 
presented as a percent reduction of baseline for ST tension, and 
PTT, with a normalized percent increase of TF ( =  [%increase 
of TF - %increase of TF in baseline] / [100 - %increase of 
TF in baseline]) [12]. The effective concentrations (EC) of 
bupivacaine, and rocuronium for ST, and TF were determined 
by probit model. The concentration-response curves of 
bupivacaine for ST, PTT, and TF, and rocuronium for ST, and TF 
were plotted.
Potency ratio of ST to TF for each drug was calculated. The 
interaction between rocuronium and bupivacaine was deter-
mined using an interaction index [13].470 www.ekja.org
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The EC50’s of rocuronium given with different concentrations 
of bupivacaine were compared using a Student’s t-test with 
Bonferroni’s correction for the significance level. Differences 
were considered significant when P < 0.05.
Results
Bupivacaine created reversible and concentration-depen-
dent NM blockade. In terms of the influence of bupivacaine 
on neuromuscular conduction, tensions of ST were equal to or 
greater than each of their baseline tension at the concentrations 
less than 30 μM bupivacaine. PTT’s were nearly equal to each 
of their baseline tension at the concentrations less than 1 
μM bupivacaine, and normalized TF revealed that the decay 
of tetanic tension began to gradually increase from 0.01 μM 
bupivacaine (Fig. 1A).
The potencies of bupivacaine for ST and normalized TF 
were 50.3 (± 5.8), and 11.4 (± 1.1) μM, respectively. In view 
of the increase of normalized TF, bupivacaine interrupted 
neuromuscular conduction below its therapeutic concentration. 
The potencies of rocuronium for ST and TF were 15.5 (± 0.4), 
and 5.6 (± 0.4) μM, respectively. The potency ratios of ST to TF 
Fig. 1. Concentration-response (CR) relationship of bupivacaine. (A) shows CR curves from raw data. Tensions of ST are equal to or greater than 
each of their baseline tension at below 30 μM. PTT’s are almost equal to baseline at below 1 μM. Normalized TF shows increases in fade from 
0.01 μM. Values present mean and SEM. No SEM bars are shown because they are within the symbol. (B) shows CR curves from probit-derived 
effective CR data. EC50’s of ST, and TF are 50.3 (± 5.8), and 11.4 (± 1.1) μM, respectively. Values are mean ± SD. The scale of ordinate presents 
percentage and that of abscissa, log (concentration). ST: single twitch, PTT: peak tetanic tension, TF: tetanic fade.
Fig. 2. In view of the cumulative concentration-effect curves for rocuronium on a ST at 0.1 Hz (A) and TF at 50 Hz for 1.9 seconds (B), 
bupivacaine shifts curves to the left; hence, the drug augments the potency of rocuronium. Bupivacaine of 10 μM causes 36.8% increase of 
TF. The unit of concentrations for bupivacaine is μM. The scale of ordinate presents percentage, and that of abscissa, log (concentration). 
The values of concentration are mean ± SD. No SD bars are shown because they are within the symbol. Bp represents bupivacaine, and R, 
rocuronium. *, or 
‡ indicates P < 0.05, vs all the rest groups, 
† indicates P < 0.05, vs R alone, or Bp 0.1, and 
§ indicates P < 0.05, vs R alone.471 www.ekja.org
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for bupivacaine and rocuronium were approximately 4.5 (± 0.8) 
and 2.8 (± 0.3), respectively (P = 0.001) (Fig. 1B).
Bupivacaine of 1.0 and 10 μM significantly shifted to left the 
concentration-response curve of rocuronium for ST and TF (Fig. 
2). Bupivacaine of 10 μM caused approximately 36.8% increase 
of normalized TF (Fig. 2B). The interaction indices for a ST 
and TF were both approximately 0.8 with bupivacaine 1.0 μM. 
Because the interaction indices were less than one, rocuronium, 
and bupivacaine interacted synergistically.
An amount of bupivacaine which needed to decay a tetanic 
tension was smaller than an amount of bupivacaine which 
needed to inhibit ST tension (Fig. 1 and 2).
Discussion
LAs primarily inhibit voltage-gated Na
+ channels [2]. How-
ever, LAs noncompetitively inhibit the ion channel activity of 
muscle-type nicotinic AChR at a therapeutic dose [4]. It has 
been known that some local anesthetics has neuromuscular 
block and potentiates nondepolarizing NM blockers [8-11]. 
Despite a commonly used LA, it still remains to investigate what 
effect bupivacaine has on NM conduction and rocuronium-
induced NM blockade.
Our results demonstrated that bupivacaine can inhibit NM 
conduction below therapeutic concentration of bupivacaine, 
when the decay of tetanic tension was examined [14,15]. 
Normalized TF began to increase from bupivacaine of the 
smallest concentration studied. If an inhibition of ST would be 
used as a tool to seek a NM interruption produced by bupiva-
caine, we would have failed to find the NM blockade induced 
by bupivacaine of the lower concentrations studied. Probably 
bupivacaine seems to produce TF in two ways: bupivacaine has 
a higher affinity for open state than for closed state of AChR ion 
channel [16-18] and may depress ACh synthesis presynaptically 
[1]. 
In addition, LA has a higher affinity for open and inactivated 
states of Na
+ channel (phasic block) than for resting (closed) 
states (tonic block) [19,20]; phasic block of Na
+ current by 
bupivacaine may block motor nerve impulses and may seem to 
some extent, to contribute to enhancing TF as concentrations 
of LA equal to those required to block nerve impulses that 
reduce chemically gated postjunctional currents of the nicotinic 
AChR [2,4]. Most of the drugs generate TF increase at lower 
concentration than do ST inhibition except for gentamicin, 
which causes ST reduction at lower concentration than does TF 
increase [12].
At the concentrations less than 30 μM, bupivacaine poten-
tiated the tensions of ST above those of the baseline, even 
if bupivacaine would bind to and inhibit nicotinic AChR of 
muscle [21], and voltage gated Na
+ channel of motor nerve [2]. 
The twitch potentiation sustained despite the development 
of tetanic fade and partial inhibition of PTT. In view of these 
results, it would seem likely that bupivacaine may augment the 
probability of ACh release in the active zone of nerve terminal 
and produce the resultant twitch augmentation. Of course, 
this hypothesis needs to be examined with some sophisticated 
method, such as binomial analysis of quantal transmitter 
release [22].
The inhibition of ST appeared at higher concentrations of 
bupivacaine. LAs inhibit channel opening, increase inactive 
form of AChR [4,21] and decrease the mean open time of ion 
channel of AChR [3]. In addition of its effect on NM junction, 
depression of motor nerve conduction would play some role 
in inhibiting ST [23]. Based on the dual phases of the effect of 
bupivacaine on ST, it seems likely that at higher concentration 
of bupivacaine the mechanism of ST inhibition dominated that 
of ST potentiation.
Elmqvist and Quastel [24] showed that the rapid decline in 
the quantum content of the end plate potentials seen in the 
beginning of tetanus can be attributed to depletion of readily 
releasable ACh in active zones. According to their conclusion, 
early part of tetanic tension (less than 10 impulses (0.2 s) in 
50 Hz of tetanic stimulation) would correspond to a tension 
which is produced by ACh released from a store of readily 
releasable ACh. So, we measured a tetanic tension at 0.2 s 
after tetanic stimulation and termed it as PTT. In our results, 
even though an increase of TF grew, the magnitude of PTT 
was equal to or greater than that of the baseline tension at 
the concentrations less than or equal to 1.0 μM bupivacaine. 
Therefore, at those concentrations bupivacaine seemed to not 
hinder a replenishment of a store of readily releasable ACh 
following a tetanic stimulation. In addition, it appears likely that 
bupivacaine may augment the probability of ACh release and 
may not make the mean open time of ion channel sufficiently 
shorten to decrease the amplitude of PTT [3].
After extradurally injecting bupivacaine (0.5% [20 ml], total 
dose: 100 mg), maximum concentration of bupivacaine is 
1.69 (0.34) μM, and after 90 min, the concentration was above 
0.92 μM [14]. The increase of normalized TF began to develop 
at the lowest concentration studied. This result showed that 
bupivacaine of a therapeutic concentration could cause NM 
blockade. The possible mechanisms might be considered as 
follows: reducing the mean open time by blocking open ion 
channels [3,21], depressing ACh mobilization during tetanic 
stimulation [1,4], and accelerating early excretion of stored 
ACh to exaggerate an increase of TF. In case of appearance of 
TF at lower concentration of a drug, a tetanic stimulation may 
be appropriate as a tool to be used for seeking NM blockade of 
the drug. It seems rare that a study on a contraction tension of 
muscle preparation has shown an inhibitory effect produced by 472 www.ekja.org
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LAs below its therapeutic concentration.
Potency ratio of ST to TF for bupivacaine was greater than 
that for rocuronium. The two drugs may have mechanisms 
in causing a decayed tetanic tension as follows: rocuronium 
occludes AChR and reduces ACh mobilization. In contrast, 
bupivacaine blocks open ion channels of AChR and reduces 
ACh synthesis. Although there is no specific known reason, the 
ion channel blockade by bupivacaine may be more efficient 
than AChR blockade by rocuronium in causing TF.
Together with its inhibition of NM transmission, bupivacaine 
facilitated NM blockade caused by rocuronium. Epidurally 
administered lidocaine, mepivacaine, and levobupivacaine 
delayed the recovery from vecuronium-induced NM blockade 
[8,9,11,25]. Wang et al. [10] demonstrated that procaine and 
lidocaine enhanced the inhibitory effect of vecuronium, and 
cisatracurium, at adult muscle-type nicotinic acetylcholine 
receptors. Therefore, like other LAs, bupivacaine may also 
potentiate the effect of nondepolarizing NM blockers. However, 
some investigators indicated that lidocaine failed to show a 
sparing effect on cisatracurium requirements [6,7]. 
It has been proposed that an interaction index between 
0.9 and 1.1 designates an additive interaction [26]. Thus, the 
interaction indices in this study indicate that rocuronium, and 
bupivacaine were synergistic in the NM blockade. Although 
it remains to be tested, several phenomena may account for 
the synergy of the two drugs. If one of them would be listed, 
mutually nonexclusive drugs contain an element of intrinsic 
synergy, which may contribute to the overall synergism [26]. 
Since they act on the different sites in AChR ion channel 
complex [27], rocuronium, and bupivacaine may be mutually 
nonexclusive and offer some degree of intrinsic synergism. 
Although the interaction is small, anesthesiologists should bear 
this interaction in mind when conducting both general and 
epidural anesthesia.
Normalized TF revealed NM blockade induced by bupiva-
caine of therapeutic concentrations. Diaphragmatic contraction 
for inspiration corresponds to tetanus for 2 s, when breath rate 
is 10/min, though the neuronal respiratory drive is 10-20 Hz 
during inspiration [28]. However, the physiologic frequency 
for a tetanic response is 30 to 50 Hz [29]. This has important 
physiologic implications because it implies that 50-Hz tetanus is 
the maximum tetanus that should be applied during peripheral 
nerve stimulation [30]. Furthermore, 50-Hz stimulation made 
a tetanic tension of baseline ascend. The increase of TF for the 
baseline tetanic tension had a negative value. Thus, the increase 
of TF in baseline tetanic tension was made zero by normali-
zation. Based on the above findings, it appears appropriate for 
normalization of TF to be applied to the study on NM blockade 
caused by bupivacaine.
In conclusion, clinicians should be aware that at its thera-
peutic concentrations, bupivacaine by itself interrupt NM 
conduction and thereby enhancing rocuronium-induced NM 
blockade.
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